Ironwood Pharmaceuticals IRWD Payment-in-kind interest
Payment-in-kind interest at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaidInKindInterest.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's payment-in-kind interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's payment-in-kind interest?
- Ironwood Pharmaceuticals (IRWD) reported payment-in-kind interest of $419K in Q1 2026.
- How has Ironwood Pharmaceuticals's payment-in-kind interest changed year-over-year?
- Ironwood Pharmaceuticals's payment-in-kind interest increased by 0.7% year-over-year, from $416K to $419K.
- What does payment-in-kind interest mean?
- This represents interest expense that is settled by issuing additional debt or equity instruments rather than through cash payments. It serves as a non-cash adjustment to net income, reflecting the accrual of debt obligations that will require future settlement. Monitoring this helps investors understand the company's reliance on non-cash financing methods to manage its interest burden.